schliessen

Filtern

 

Bibliotheken

Biomarkers of response and resistance to antiangiogenic therapy

No validated biological markers (or biomarkers) currently exist for appropriately selecting patients with cancer for antiangiogenic therapy. Nor are there biomarkers identifying escape pathways that should be targeted after tumors develop resistance to a given antiangiogenic agent. A number of poten... Full description

Journal Title: Nature reviews. Clinical oncology 2009-06, Vol.6 (6), p.327-338
Main Author: Jain, Rakesh K
Other Authors: Duda, Dan G , Willett, Christopher G , Sahani, Dushyant V , Zhu, Andrew X , Loeffler, Jay S , Batchelor, Tracy T , Sorensen, A. Gregory
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: England: Nature Publishing Group
ID: ISSN: 1759-4774
Link: https://www.ncbi.nlm.nih.gov/pubmed/19483739
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3057433
title: Biomarkers of response and resistance to antiangiogenic therapy
format: Article
creator:
  • Jain, Rakesh K
  • Duda, Dan G
  • Willett, Christopher G
  • Sahani, Dushyant V
  • Zhu, Andrew X
  • Loeffler, Jay S
  • Batchelor, Tracy T
  • Sorensen, A. Gregory
subjects:
  • Angiogenesis inhibitors
  • Angiogenesis Inhibitors - therapeutic use
  • Article
  • Biological markers
  • Biomarkers, Tumor - metabolism
  • Drug resistance
  • Drug Resistance, Neoplasm
  • Health aspects
  • Humans
  • Neoplasms - blood supply
  • Neoplasms - metabolism
  • Neovascularization, Pathologic - metabolism
  • Neovascularization, Pathologic - prevention & control
  • Usage
  • Vascular Endothelial Growth Factor A - antagonists & inhibitors
  • Vascular Endothelial Growth Factor A - metabolism
ispartof: Nature reviews. Clinical oncology, 2009-06, Vol.6 (6), p.327-338
description: No validated biological markers (or biomarkers) currently exist for appropriately selecting patients with cancer for antiangiogenic therapy. Nor are there biomarkers identifying escape pathways that should be targeted after tumors develop resistance to a given antiangiogenic agent. A number of potential systemic, circulating, tissue and imaging biomarkers have emerged from recently completed phase I-III studies. Some of these are measured at baseline (for example VEGF polymorphisms), others are measured during treatment (such as hypertension, MRI-measured K(trans), circulating angiogenic molecules or collagen IV), and all are mechanistically based. Some of these biomarkers might be pharmacodynamic (for example, increase in circulating VEGF, placental growth factor) while others have potential for predicting clinical benefit or identifying the escape pathways (for example, stromal-cell-derived factor 1alpha, interleukin-6). Most biomarkers are disease and/or agent specific and all of them need to be validated prospectively. We discuss the current challenges in establishing biomarkers of antiangiogenic therapy, define systemic, circulating, tissue and imaging biomarkers and their advantages and disadvantages, and comment on the future opportunities for validating biomarkers of antiangiogenic therapy.
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 1759-4774
fulltext: fulltext
issn:
  • 1759-4774
  • 1759-4782
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.7039573
LOCALfalse
PrimoNMBib
record
control
sourceidgale_pubme
recordidTN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3057433
sourceformatXML
sourcesystemPC
galeidA201551136
sourcerecordidA201551136
originalsourceidFETCH-LOGICAL-1625t-e2611f57fda686635b50352e50fc32b0f4b48b0d5ccf1165fa44059d143e19d83
addsrcrecordideNp9UstuEzEUHSEQfcAHsEGRkMoqwW_PbKhKVShSJTawtjz2deIysYPtQerf41GiNCkIeXHt63POfTbNG4wWGNH2Q0hm8CEGsyAIdQtBnzWnWPJuzmRLnu_vkp00ZznfIyQEk_Rlc4I71lJJu9Pm8pOPa51-Qsqz6GYJ8iaGDDMd7PTwuehgYFZi9RSvw9LHJQRvZmUFSW8eXjUvnB4yvN7Z8-bH55vv17fzu29fvl5f3c2xILzMgQiMHZfOatEKQXnPEeUEOHKGkh451rO2R5Yb4zAW3GnGEO8sZhRwZ1t63nzc6m7Gfg3WQChJD2qTfM3-QUXt1fFP8Cu1jL8VRVwySqvA7VYgbiBon-CIawMUFa0iQireUawJb1GPTNcaQUhrqzVSM86xtFXqYpdLir9GyEWtfTYwDDpAHLMSkmKG0BTz3RPgfRxTqH1SGJGulUxi8oha6gGUDy7WAswkqa4IwjUmpqKiFv9A1WNh7U0M4Hz1HxEuDggr0ENZ5TiMxdcBHwPxFmhSzDmB23cGIzXtmdrvmZr2TImpsreH43hk7BarAuQTUeOLnmLXtP3wX-n3W2bQZTwY09_IP5C_7jk
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
pqid1029874712
display
typearticle
titleBiomarkers of response and resistance to antiangiogenic therapy
sourceAlma/SFX Local Collection
creatorJain, Rakesh K ; Duda, Dan G ; Willett, Christopher G ; Sahani, Dushyant V ; Zhu, Andrew X ; Loeffler, Jay S ; Batchelor, Tracy T ; Sorensen, A. Gregory
creatorcontribJain, Rakesh K ; Duda, Dan G ; Willett, Christopher G ; Sahani, Dushyant V ; Zhu, Andrew X ; Loeffler, Jay S ; Batchelor, Tracy T ; Sorensen, A. Gregory
descriptionNo validated biological markers (or biomarkers) currently exist for appropriately selecting patients with cancer for antiangiogenic therapy. Nor are there biomarkers identifying escape pathways that should be targeted after tumors develop resistance to a given antiangiogenic agent. A number of potential systemic, circulating, tissue and imaging biomarkers have emerged from recently completed phase I-III studies. Some of these are measured at baseline (for example VEGF polymorphisms), others are measured during treatment (such as hypertension, MRI-measured K(trans), circulating angiogenic molecules or collagen IV), and all are mechanistically based. Some of these biomarkers might be pharmacodynamic (for example, increase in circulating VEGF, placental growth factor) while others have potential for predicting clinical benefit or identifying the escape pathways (for example, stromal-cell-derived factor 1alpha, interleukin-6). Most biomarkers are disease and/or agent specific and all of them need to be validated prospectively. We discuss the current challenges in establishing biomarkers of antiangiogenic therapy, define systemic, circulating, tissue and imaging biomarkers and their advantages and disadvantages, and comment on the future opportunities for validating biomarkers of antiangiogenic therapy.
identifier
0ISSN: 1759-4774
1EISSN: 1759-4782
2DOI: 10.1038/nrclinonc.2009.63
3PMID: 19483739
4CODEN: AJHYE6
languageeng
publisherEngland: Nature Publishing Group
subjectAngiogenesis inhibitors ; Angiogenesis Inhibitors - therapeutic use ; Article ; Biological markers ; Biomarkers, Tumor - metabolism ; Drug resistance ; Drug Resistance, Neoplasm ; Health aspects ; Humans ; Neoplasms - blood supply ; Neoplasms - metabolism ; Neovascularization, Pathologic - metabolism ; Neovascularization, Pathologic - prevention & control ; Usage ; Vascular Endothelial Growth Factor A - antagonists & inhibitors ; Vascular Endothelial Growth Factor A - metabolism
ispartofNature reviews. Clinical oncology, 2009-06, Vol.6 (6), p.327-338
rights
0COPYRIGHT 2009 Nature Publishing Group
1Copyright Nature Publishing Group Jun 2009
22009 Macmillan Publishers Limited. All rights reserved 2009
lds50peer_reviewed
oafree_for_read
citedbyFETCH-LOGICAL-1625t-e2611f57fda686635b50352e50fc32b0f4b48b0d5ccf1165fa44059d143e19d83
citesFETCH-LOGICAL-1625t-e2611f57fda686635b50352e50fc32b0f4b48b0d5ccf1165fa44059d143e19d83
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19483739$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Jain, Rakesh K
1Duda, Dan G
2Willett, Christopher G
3Sahani, Dushyant V
4Zhu, Andrew X
5Loeffler, Jay S
6Batchelor, Tracy T
7Sorensen, A. Gregory
title
0Biomarkers of response and resistance to antiangiogenic therapy
1Nature reviews. Clinical oncology
addtitleNat Rev Clin Oncol
descriptionNo validated biological markers (or biomarkers) currently exist for appropriately selecting patients with cancer for antiangiogenic therapy. Nor are there biomarkers identifying escape pathways that should be targeted after tumors develop resistance to a given antiangiogenic agent. A number of potential systemic, circulating, tissue and imaging biomarkers have emerged from recently completed phase I-III studies. Some of these are measured at baseline (for example VEGF polymorphisms), others are measured during treatment (such as hypertension, MRI-measured K(trans), circulating angiogenic molecules or collagen IV), and all are mechanistically based. Some of these biomarkers might be pharmacodynamic (for example, increase in circulating VEGF, placental growth factor) while others have potential for predicting clinical benefit or identifying the escape pathways (for example, stromal-cell-derived factor 1alpha, interleukin-6). Most biomarkers are disease and/or agent specific and all of them need to be validated prospectively. We discuss the current challenges in establishing biomarkers of antiangiogenic therapy, define systemic, circulating, tissue and imaging biomarkers and their advantages and disadvantages, and comment on the future opportunities for validating biomarkers of antiangiogenic therapy.
subject
0Angiogenesis inhibitors
1Angiogenesis Inhibitors - therapeutic use
2Article
3Biological markers
4Biomarkers, Tumor - metabolism
5Drug resistance
6Drug Resistance, Neoplasm
7Health aspects
8Humans
9Neoplasms - blood supply
10Neoplasms - metabolism
11Neovascularization, Pathologic - metabolism
12Neovascularization, Pathologic - prevention & control
13Usage
14Vascular Endothelial Growth Factor A - antagonists & inhibitors
15Vascular Endothelial Growth Factor A - metabolism
issn
01759-4774
11759-4782
fulltexttrue
rsrctypearticle
creationdate2009
recordtypearticle
recordideNp9UstuEzEUHSEQfcAHsEGRkMoqwW_PbKhKVShSJTawtjz2deIysYPtQerf41GiNCkIeXHt63POfTbNG4wWGNH2Q0hm8CEGsyAIdQtBnzWnWPJuzmRLnu_vkp00ZznfIyQEk_Rlc4I71lJJu9Pm8pOPa51-Qsqz6GYJ8iaGDDMd7PTwuehgYFZi9RSvw9LHJQRvZmUFSW8eXjUvnB4yvN7Z8-bH55vv17fzu29fvl5f3c2xILzMgQiMHZfOatEKQXnPEeUEOHKGkh451rO2R5Yb4zAW3GnGEO8sZhRwZ1t63nzc6m7Gfg3WQChJD2qTfM3-QUXt1fFP8Cu1jL8VRVwySqvA7VYgbiBon-CIawMUFa0iQireUawJb1GPTNcaQUhrqzVSM86xtFXqYpdLir9GyEWtfTYwDDpAHLMSkmKG0BTz3RPgfRxTqH1SGJGulUxi8oha6gGUDy7WAswkqa4IwjUmpqKiFv9A1WNh7U0M4Hz1HxEuDggr0ENZ5TiMxdcBHwPxFmhSzDmB23cGIzXtmdrvmZr2TImpsreH43hk7BarAuQTUeOLnmLXtP3wX-n3W2bQZTwY09_IP5C_7jk
startdate200906
enddate200906
creator
0Jain, Rakesh K
1Duda, Dan G
2Willett, Christopher G
3Sahani, Dushyant V
4Zhu, Andrew X
5Loeffler, Jay S
6Batchelor, Tracy T
7Sorensen, A. Gregory
generalNature Publishing Group
scope
0CGR
1CUY
2CVF
3ECM
4EIF
5NPM
6AAYXX
7CITATION
83V.
97RV
107T5
117TM
127TO
137X7
147XB
1588E
168FE
178FH
188FI
198FJ
208FK
21ABUWG
22AZQEC
23BBNVY
24BENPR
25BHPHI
26DWQXO
27FYUFA
28GHDGH
29GNUQQ
30H94
31HCIFZ
32K9.
33KB0
34LK8
35M0S
36M1P
37M7P
38NAPCQ
39PQEST
40PQQKQ
41PQUKI
42PRINS
437X8
44BOBZL
45CLFQK
465PM
sort
creationdate200906
titleBiomarkers of response and resistance to antiangiogenic therapy
authorJain, Rakesh K ; Duda, Dan G ; Willett, Christopher G ; Sahani, Dushyant V ; Zhu, Andrew X ; Loeffler, Jay S ; Batchelor, Tracy T ; Sorensen, A. Gregory
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1625t-e2611f57fda686635b50352e50fc32b0f4b48b0d5ccf1165fa44059d143e19d83
rsrctypearticles
prefilterarticles
languageeng
creationdate2009
topic
0Angiogenesis inhibitors
1Angiogenesis Inhibitors - therapeutic use
2Article
3Biological markers
4Biomarkers, Tumor - metabolism
5Drug resistance
6Drug Resistance, Neoplasm
7Health aspects
8Humans
9Neoplasms - blood supply
10Neoplasms - metabolism
11Neovascularization, Pathologic - metabolism
12Neovascularization, Pathologic - prevention & control
13Usage
14Vascular Endothelial Growth Factor A - antagonists & inhibitors
15Vascular Endothelial Growth Factor A - metabolism
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Jain, Rakesh K
1Duda, Dan G
2Willett, Christopher G
3Sahani, Dushyant V
4Zhu, Andrew X
5Loeffler, Jay S
6Batchelor, Tracy T
7Sorensen, A. Gregory
collection
0Medline
1MEDLINE
2MEDLINE (Ovid)
3MEDLINE
4MEDLINE
5PubMed
6CrossRef
7ProQuest Central (Corporate)
8Nursing & Allied Health Database
9Immunology Abstracts
10Nucleic Acids Abstracts
11Oncogenes and Growth Factors Abstracts
12Health & Medical Collection
13ProQuest Central (purchase pre-March 2016)
14Medical Database (Alumni Edition)
15ProQuest SciTech Collection
16ProQuest Natural Science Collection
17Hospital Premium Collection
18Hospital Premium Collection (Alumni Edition)
19ProQuest Central (Alumni) (purchase pre-March 2016)
20ProQuest Central (Alumni Edition)
21ProQuest Central Essentials
22Biological Science Collection
23ProQuest Central
24Natural Science Collection
25ProQuest Central Korea
26Health Research Premium Collection
27Health Research Premium Collection (Alumni)
28ProQuest Central Student
29AIDS and Cancer Research Abstracts
30SciTech Premium Collection
31ProQuest Health & Medical Complete (Alumni)
32Nursing & Allied Health Database (Alumni Edition)
33ProQuest Biological Science Collection
34Health & Medical Collection (Alumni Edition)
35Medical Database
36Biological Science Database
37Nursing & Allied Health Premium
38ProQuest One Academic Eastern Edition
39ProQuest One Academic
40ProQuest One Academic UKI Edition
41ProQuest Central China
42MEDLINE - Academic
43OpenAIRE (Open Access)
44OpenAIRE
45PubMed Central (Full Participant titles)
jtitleNature reviews. Clinical oncology
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Jain, Rakesh K
1Duda, Dan G
2Willett, Christopher G
3Sahani, Dushyant V
4Zhu, Andrew X
5Loeffler, Jay S
6Batchelor, Tracy T
7Sorensen, A. Gregory
formatjournal
genrearticle
ristypeJOUR
atitleBiomarkers of response and resistance to antiangiogenic therapy
jtitleNature reviews. Clinical oncology
addtitleNat Rev Clin Oncol
date2009-06
risdate2009
volume6
issue6
spage327
epage338
pages327-338
issn1759-4774
eissn1759-4782
codenAJHYE6
abstractNo validated biological markers (or biomarkers) currently exist for appropriately selecting patients with cancer for antiangiogenic therapy. Nor are there biomarkers identifying escape pathways that should be targeted after tumors develop resistance to a given antiangiogenic agent. A number of potential systemic, circulating, tissue and imaging biomarkers have emerged from recently completed phase I-III studies. Some of these are measured at baseline (for example VEGF polymorphisms), others are measured during treatment (such as hypertension, MRI-measured K(trans), circulating angiogenic molecules or collagen IV), and all are mechanistically based. Some of these biomarkers might be pharmacodynamic (for example, increase in circulating VEGF, placental growth factor) while others have potential for predicting clinical benefit or identifying the escape pathways (for example, stromal-cell-derived factor 1alpha, interleukin-6). Most biomarkers are disease and/or agent specific and all of them need to be validated prospectively. We discuss the current challenges in establishing biomarkers of antiangiogenic therapy, define systemic, circulating, tissue and imaging biomarkers and their advantages and disadvantages, and comment on the future opportunities for validating biomarkers of antiangiogenic therapy.
copEngland
pubNature Publishing Group
pmid19483739
doi10.1038/nrclinonc.2009.63
oafree_for_read